We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




MicroRNA Downregulation Boosts Growth of Acute Myeloid Leukemia Cells

By LabMedica International staff writers
Posted on 10 May 2016
Print article
Image: A photomicrograph of myeloblasts in bone marrow of patient with acute myeloid leukemia (AML) (Photo courtesy of Wikimedia Commons).
Image: A photomicrograph of myeloblasts in bone marrow of patient with acute myeloid leukemia (AML) (Photo courtesy of Wikimedia Commons).
Acute myeloid leukemia (AML) cells have developed a mechanism to suppress the activity of the microRNA miR-22, which would otherwise act to block their growth.

AML is a cancer of the myeloid line of blood cells, characterized by the rapid growth of abnormal white blood cells that accumulate in the bone marrow and interfere with the production of normal blood cells. The symptoms of AML are caused by replacement of normal bone marrow with leukemic cells, which causes a drop in red blood cells, platelets, and normal white blood cells. Symptoms include fatigue, shortness of breath, easy bruising and bleeding, and increased risk of infection. AML progresses rapidly and is typically fatal within weeks or months if left untreated.

Investigators at the University of Cincinnati (OH, USA) worked mainly with AML cells growing in culture. They reported in the April 26, 2016, online edition of the journal Nature Communications that the microRNA miR-22 was an essential tumor suppressor and that it was significantly downregulated in AML. Forced expression of miR-22 significantly suppressed leukemic cell viability and growth in vitro and substantially inhibited leukemia development and maintenance in vivo.

The investigators found that at the molecular level miR-22 targeted multiple oncogenes, including CRTC1 (CREB-regulated transcription coactivator 1), FLT3 (Fms-like tyrosine kinase 3) and MYCBP (C-Myc-binding protein), and thus repressed the CREB and MYC pathways. The downregulation of miR-22 in AML was caused by the activity of the TET1/GFI1/EZH2/SIN3A signaling pathway and/or by DNA copy-number loss. Furthermore, nanoparticles carrying miR-22 oligonucleotides significantly inhibited leukemia progression in vivo.

"MicroRNAs make up a class of small, non-coding internal RNAs that control a gene’s job, or expression, by directing their target messaging RNAs, or mRNAs, to inhibit or stop. Cellular organisms use mRNA to convey genetic information,” said senior author Dr. Jianjun Chen, associate professor of cancer biology at the University of Cincinnati. "When we forced miR-22 expression, we saw difficulty in leukemia cells developing, growing and thriving. miR-22 targets multiple cancer causing genes (CRTC1, FLT3 and MYCBP) and blocks certain pathways (CREB and MYC). The down-regulation, or decreased output, of miR-22 in AML is caused by the loss of the number of DNA being copied and/or stopping their expression through a pathway called TET1/GFI1/EZH2/SIN3A. Also, nanoparticles carrying miR-22 DNA oligonucleotides (short nucleic acid molecules) prevented leukemia advancement. More research on this pathway and ways to target it are necessary.”

Related Links:
University of Cincinnati

Gold Member
Turnkey Packaging Solution
HLX
Unit-Dose Packaging solution
HLX
New
Incubator
HettCube 120
New
Urine Bone Markers Control
Lyphochek Urine Bone Markers Control

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Molecular Diagnostics

view channel
Image: The FDA clearance for the QIAstat-Dx Respiratory Panel Mini test follows the recent approval of QIAstat-Dx Respiratory Panel Plus (Photo courtesy of QIAGEN)

Respiratory Panel to Help Clinicians Make Precise Treatment Decisions in Outpatient Settings

Respiratory tract infections are the primary reason for visits to emergency departments and subsequent hospitalizations. In the U.S., it is estimated that there are up to 41 million cases of influenza... Read more

Hematology

view channel
Image: QScout CBC will give a complete blood count in 2 minutes from fingerstick or venous blood (Photo courtesy of Ad Astra Diagnostics)

Next Gen CBC and Sepsis Diagnostic System Targets Faster, Earlier, Easier Results

Every hour is critical in protecting patients from infections, yet there are currently limited tools to assist in early diagnosis before patients reach a hospital. The complete blood count (CBC) is a common... Read more

Microbiology

view channel
Image: The InfectoSynovia test has the potential to revolutionize the diagnosis of periprosthetic joint infection (Photo courtesy of 123RF)

High-Accuracy Bedside Test to Diagnose Periprosthetic Joint Infection in Five Minutes

Periprosthetic joint infection (PJI) represents a significant global issue that is worsening as the number of joint replacements increases due to aging populations. In the United States alone, the anticipated... Read more

Pathology

view channel
Image: The new technique allows properties of cancer cells and their surrounding tissue to be analyzed in detail at single-cell level (Photo courtesy of Universität Helsinki/Karolina Punovuori)

New Imaging Method Opens Door to Precision Diagnostics for Head and Neck Cancers

Head and neck cancers, while considered rare, represent a significant portion of cancer cases and have seen a notable increase over the past 30 years. These cancers encompass various malignant tumors that... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.